RT Journal Article
T1 Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
A1 Angel Calleja, Miguel
A1 Albanell, Joan
A1 Aranda, Enrique
A1 Garcia-Foncillas, Jesus
A1 Feliu, Anna
A1 Rivera, Fernando
A1 Oyaguez, Itziar
A1 Salinas-Ortega, Laura
A1 Soto Alvarez, Javier
K1 economics
K1 pharmaceutical
K1 public health
K1 medical oncology
K1 antineoplastic agents
K1 health care economics and organizations
K1 Lung-cancer
K1 Recurrent
AB Objective To assess the economic impact of introducing biosimilars of bevacizumab for the management of cancer patients receiving systemic bevacizumab in the National Health System (SNHS) of Spain. Methods A 3-year budget impact analysis model was adapted to estimate the cost of introducing biosimilars of bevacizumab in the SNHS for the adult population who were candidates to receive treatment with bevacizumab. Values for the estimation of the population were obtained from the literature and were validated by an expert panel. In this analysis only pharmaceutical costs (euro, year 2021) obtained from official databases were considered. A sensitivity analysis was performed to examine the robustness of the model. Results The introduction of bevacizumab biosimilars would generate an annual cost saving of euro11 558 268 (-5.1%) for the first year with a penetration share of biosimilars from 30.0%, euro29 126 373 (-8.5%) for the second year with a share of 50.0% and euro52 361 778 (-13.6%) for the third year with a share of 80.0%. The total pharmaceutical costs of the scenario without biosimilars are euro227 033 352 for the first year, euro342 663 209 for the second year and euro385 013 076 for the third year. In contrast, the pharmaceutical costs of the scenario with bevacizumab biosimilars are euro215 475 084, euro313 536 836 and euro332 651 297 for years 1, 2 and 3, respectively. Conclusions The introduction of biosimilars in the Spanish Health System would generate saving costs in the pharmacological budget to boost biological drugs from the first year.
PB Bmj publishing group
SN 2047-9956
YR 2021
FD 2021-11-21
LK https://hdl.handle.net/10668/25589
UL https://hdl.handle.net/10668/25589
LA en
DS RISalud
RD Apr 17, 2025